Tamoxifen, pills 20mg, 30pcs – Ozon

Composition

1 tablet contains:

Active ingredients:

tamoxifen citrate is 30.4 mg, which is equivalent to a tamoxifen content of 20 mg.

Auxiliary substances:

corn starch,

lactose monohydrate,

povidone,

sodium starch glycolate,

magnesium stearate,

purified water.

Indications

• Breast cancer in menopausal women;
• breast cancer in men after castration;
• kidney cancer;
• melanoma (containing estrogen receptors);
• ovarian cancer;
• prostate cancer with resistance to other drugs.

Contraindications

• Thrombophlebitis;
• pregnancy;
• hypersensitivity to tamoxifen.

Side effects

From the digestive system: nausea, vomiting, increased activity of hepatic transaminases; in some cases – fatty liver infiltration, cholestasis, hepatitis.

From the central nervous system: rarely – depression, dizziness, headache, retrobulbar neuritis.

From the side of the visual organ: rarely-retinopathy, keratopathy, cataract.

From the hematopoietic system: rarely-thrombocytopenia, leukopenia.

From the endocrine system: in women-endometrial hyperplasia, vaginal bleeding, hot flashes, weight gain; in men-impotence, decreased libido.

From the cardiovascular system:  edema, thromboembolism, phlebitis.

Dermatological reactions: alopecia, rash, itching.

Other services: pain in the bones and lesions, increased body temperature.

Interaction

When used concomitantly with anticoagulants coumarin derivatives, the risk of increased anticoagulant action increases; with cytostatics, the risk of thrombosis may increase.

When used concomitantly with allopurinol, a hepatotoxic effect is possible; with aminoglutetimide, a decrease in the concentration of tamoxifen in plasma, apparently due to an increase in its metabolism.

Patients receiving tamoxifen may experience prolonged neuromuscular blockage caused by atracurium.

Concomitant use of bromocriptine may increase the dopaminergic effect of bromocriptine. In patients receiving tamoxifen, when using warfarin, there is a risk of developing a threatening clinical situation: prolongation of prothrombin time, hematuria, and hematoma are possible.

When used concomitantly with mitomycin, the risk of developing hemolytic-uremic syndrome increases.

A decrease in the concentration of tamoxifen in blood plasma is possible, which is probably due to the induction of the CYP3A4 isoenzyme under the action of rifampicin.

Estrogens may reduce the therapeutic effect of tamoxifen.

How to take, course of use and dosage

The dosage regimen is set individually, depending on the indications, the patient’s condition and the antitumor therapy regimen used.

Overdose

No acute tamoxifen overdose has been observed in humans.

Symptoms: it should be expected that an overdose may cause an increase in the above-described adverse reactions.

Treatment: There are no specific antidotes, and treatment should be symptomatic.

Storage conditions

Store at a temperature of 15-25 °C.

Shelf

life is 2 years.

Active ingredient

Tamoxifen

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Cancer, Breast Cancer